Effect of artesunate-mefloquine fixed-dose combination in malaria transmission in amazon basin communities

Imagem de Miniatura
Arquivos
art_Boulos_Effect_of_artesunate_mefloquine_fixed_dose_combination_in_2012.PDF (973.8 KB)
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
Santelli, Ana C.
Ribeiro, Isabela
Daher, Andre
Marchesini, Paola B.
dos Santos, Roseli La Corte
Lucena, Marize B. F.
Magalhaes, Izanelda
Leon, Antonio P.
Junger, Washington
Citação
MALARIA JOURNAL, v.11, article ID 286, 12p, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Studies in South-East Asia have suggested that early diagnosis and treatment with artesunate (AS) and mefloquine (MQ) combination therapy may reduce the transmission of Plasmodium falciparum malaria and the progression of MQ resistance. Methods: The effectiveness of a fixed-dose combination of AS and MQ (ASMQ) in reducing malaria transmission was tested in isolated communities of the Jurua valley in the Amazon region. Priority municipalities within the Brazilian Legal Amazon area were selected according to pre-specified criteria. Routine national malaria control programmatic procedures were followed. Existing health structures were reinforced and health care workers were trained to treat with ASMQ all confirmed falciparum malaria cases that match inclusion criteria. A local pharmacovigilance structure was implemented. Incidence of malaria and hospitalizations were recorded two years before, during, and after the fixed-dose ASMQ intervention. In total, between July 2006 and December 2008, 23,845 patients received ASMQ. Two statistical modelling approaches were applied to monthly time series of P. falciparum malaria incidence rates, P. falciparum/Plasmodium vivax infection ratio, and malaria hospital admissions rates. All the time series ranged from January 2004 to December 2008, whilst the intervention period span from July 2006 to December 2008. Results: The ASMQ intervention had a highly significant impact on the mean level of each time series, adjusted for trend and season, of 0.34 (95% CI 0.20 - 0.58) for the P. falciparum malaria incidence rates, 0.67 (95% CI 0.50 - 0.89) for the P. falciparum/P. vivax infection ratio, and 0.53 (95% CI 0.41 - 0.69) for the hospital admission rates. There was also a significant change in the seasonal (or monthly) pattern of the time series before and after intervention, with the elimination of the malaria seasonal peak in the rainy months of the years following the introduction of ASMQ. No serious adverse events relating to the use of fixed-dose ASMQ were reported. Conclusions: In the remote region of the Jurua valley, the early detection of malaria by health care workers and treatment with fixed-dose ASMQ was feasible and efficacious, and significantly reduced the incidence and morbidity of P. falciparum malaria.
Palavras-chave
Malaria, ACT, artesunate, mefloquine, Fixed-dose combination, P. falciparum, Brazil, Amazon
URI
https://observatorio.fm.usp.br/handle/OPI/5024
Referências
  1. [Anonymous], 2010, GUID TREATM MAL
  2. Ashley EA, 2006, ANTIMICROB AGENTS CH, V50, P2281, DOI 10.1128/AAC.00040-06
  3. Ashley EA, 2006, TROP MED INT HEALTH, V11, P1653, DOI 10.1111/j.1365-3156.2006.01724.x
  4. Barnes KI, 2005, PLOS MED, V2, P1123, DOI 10.1371/journal.pmed.0020330
  5. Camargo K R Jr, 2000, Cad Saude Publica, V16, P439, DOI 10.1590/S0102-311X2000000200014
  6. Carrara VI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004551
  7. Carrara VI, 2006, PLOS MED, V3, P856, DOI 10.1371/journal.pmed.0030183
  8. DEANDRADE ALSS, 1995, CLIN INFECT DIS, V20, P475
  9. Denis MB, 2006, TROP MED INT HEALTH, V11, P1360, DOI 10.1111/j.1365-3156.2006.01690.x
  10. Duarte EC, 2004, AM J TROP MED HYG, V70, P229
  11. FELLEGI IP, 1969, J AM STAT ASSOC, V64, P1183, DOI 10.2307/2286061
  12. Ferreira MU, 2010, J INFECT DEV COUNTR, V4, P533
  13. Gonçalves M. J. F., 2004, Revista de Salud Pública, V6, P156
  14. KREMSNER PG, 1989, B WORLD HEALTH ORGAN, V67, P289
  15. Krudsood S, 2010, ANTIMICROB AGENTS CH, V54, P3730, DOI 10.1128/AAC.01187-09
  16. Manual de Terapeutica da Malaria, 2003, MAN TER MAL
  17. NEIFER S, 1991, REV I MED TROP, V33, P205
  18. Nosten F, 2007, AM J TROP MED HYG, V77, P181
  19. Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8
  20. NOSTEN F, 1994, J INFECT DIS, V170, P971
  21. Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
  22. Price RN, 1997, T ROY SOC TROP MED H, V91, P574, DOI 10.1016/S0035-9203(97)90032-8
  23. Ruebush TK, 2003, AM J TROP MED HYG, V68, P391
  24. Simpson JA, 2000, ANTIMICROB AGENTS CH, V44, P3414, DOI 10.1128/AAC.44.12.3414-3424.2000
  25. Smithuis F, 2010, LANCET INFECT DIS, V10, P673, DOI 10.1016/S1473-3099(10)70187-0
  26. Tadei WP, 1998, AM J TROP MED HYG, V59, P325
  27. van den Broek IV, 2005, T ROY SOC TROP MED H, V99, P727, DOI 10.1016/j.trstmh.2005.02.007
  28. World Health Organisation, 2009, WORLD MAL REP
  29. World Health Organization, 2000, T R SOC TROP MED S1, V94, P1

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/49